AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
73.8%
39M of 52M shares
Institutional holders
505
139 new, 40 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 33 sales
Net sold $134.33M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D. | 2,922,729 | 6.00% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 2,736,503 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AXSM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,103,708 | 5.93% | $759.69M | −809,136 | 0.01% |
| Vanguard Portfolio Management LLC | 1,983,514 | 3.79% | $485.50M | −74,656 | 0.02% |
| Vanguard Capital Management LLC | 1,965,086 | 3.75% | $480.99M | +27,334 | 0.01% |
| Invesco Ltd. | 1,671,684 | 3.19% | $409.18M | +374,006 | 0.03% |
| FMR LLC | 1,539,163 | 2.94% | $376.74M | −27,832 | 0.02% |
| Geode Capital Management, LLC | 967,172 | 1.85% | $236.79M | −195,809 | 0.01% |
| Assenagon Asset Management S.A. | 909,364 | 1.74% | $222.59M | +43,406 | 0.14% |
| Morgan Stanley | 804,082 | 1.54% | $196.82M | +327,381 | 0.01% |
| State Street Corp | 785,661 | 1.50% | $192.29M | −201,148 | 0.01% |
| Deep Track Capital, LP | 700,000 | 1.34% | $171.34M | −400,000 | 2.49% |
| Two Sigma Investments, LP | 669,478 | 1.28% | $163.87M | +346,700 | 0.12% |
| Franklin Resources Inc | 668,373 | 1.28% | $163.60M | +229,883 | 0.04% |
| Wellington Management Group Llp | 653,920 | 1.25% | $160.06M | −491,386 | 0.03% |
| Alethea Capital Management, LLC | 648,756 | 1.24% | $158.80M | −358 | 65.78% |
| Price T Rowe Associates Inc /Md/ | 642,893 | 1.23% | $157.36K | −674,166 | 0.02% |
| D. E. Shaw & Co., Inc. | 604,753 | 1.15% | $148.03M | +1,288 | 0.07% |
| Millennium Management LLC | 556,088 | 1.06% | $136.11M | +535,330 | 0.05% |
| Nomura Asset Management International Inc. | 539,407 | 1.03% | $132.03M | −273,402 | 0.20% |
| Norges Bank | 514,266 | 0.98% | $125.88M | New | 0.01% |
| First Trust Advisors LP | 482,061 | 0.92% | $117.99M | −95,418 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 505 | 39M | 73.8% | 139 / 161 | 157 / 40 | 8M | 7M |
| Q1 2026 | 410 | 38M | 72.4% | 71 / 146 | 142 / 53 | 9M | 5M |
| Q4 2025 | 399 | 38M | 71.9% | 87 / 139 | 122 / 34 | 6M | 6M |
| Q3 2025 | 355 | 37M | 71.5% | 49 / 146 | 105 / 40 | 5M | 5M |
| Q2 2025 | 348 | 38M | 72.3% | 55 / 152 | 92 / 57 | 6M | 6M |
| Q1 2025 | 353 | 38M | 71.7% | 92 / 103 | 115 / 28 | 8M | 8M |
| Q4 2024 | 292 | 37M | 71.0% | 61 / 91 | 90 / 40 | 5M | 6M |
| Q3 2024 | 280 | 39M | 74.3% | 48 / 83 | 95 / 22 | 6M | 5M |
| Q2 2024 | 257 | 41M | 78.2% | 33 / 78 | 97 / 33 | 7M | 7M |
| Q1 2024 | 259 | 41M | 78.0% | 44 / 97 | 74 / 26 | 6M | 5M |
| Q4 2023 | 244 | 39M | 75.2% | 44 / 70 | 88 / 24 | 5M | 4M |
| Q3 2023 | 226 | 38M | 72.3% | 26 / 87 | 71 / 28 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AXSM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,388,721 | 2.65% | $339.92M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,003,488 | 1.92% | $245.62M | 0.13% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 578,233 | 1.10% | $141.53M | 0.30% | Jun 30, 2026 |
| Vanguard Explorer Fund | 531,004 | 1.01% | $115.75M | 0.52% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 495,762 | 0.95% | $121.35M | 0.12% | Jun 30, 2026 |
| Invesco Discovery Fund | 468,539 | 0.89% | $109.86M | 1.40% | May 31, 2026 |
| Nomura Small Cap Core Fund | 430,250 | 0.82% | $100.89M | 1.83% | May 29, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 426,122 | 0.81% | $104.30M | 3.71% | Jun 30, 2026 |
| iShares Biotechnology ETF | 305,148 | 0.58% | $74.69M | 0.82% | Jun 30, 2026 |
| Franklin Dynatech Fund | 300,000 | 0.57% | $73.43M | 0.24% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 286,580 | 0.55% | $67.20M | 1.28% | May 31, 2026 |
| Eventide Gilead Fund | 257,138 | 0.49% | $62.94M | 1.83% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 254,745 | 0.49% | $62.35M | 0.29% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 218,156 | 0.42% | $51.15M | 0.12% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 212,917 | 0.41% | $49.92M | 0.28% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Herriot Tabuteau | Chief Executive Officer, Director, 10% owner | 7,356,389 | 14.04% | Aug 7, 2026 |
| Mark L. Jacobson | Chief Operating Officer | 10,000 | 0.02% | Sep 3, 2026 |
| Nick Pizzie | Chief Financial Officer | 43,355 | 0.08% | Jun 9, 2026 |
| Ari Maizel | Chief Commercial Officer | 7,500 | 0.01% | Apr 23, 2026 |
| Hunter R. Murdock | General Counsel | 6,014 | 0.01% | Apr 23, 2026 |
| Roger Jeffs | Director | 105,279 | 0.20% | Jun 11, 2026 |
| Mark Coleman | Director | 434,245 | 0.83% | Jun 10, 2026 |
| Susan Mahony | Director | 829 | 0.00% | Jun 10, 2026 |
| Mark E. Saad | Director | 11,731 | 0.02% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark L. Jacobson Chief Operating Officer | Sep 3, 2026 | Option exercise | +10,000 | $12.95 | $129.50K | 10,000 |
| Mark L. Jacobson Chief Operating Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −10,000 | $208.65 | $2.09M | 0 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 6, 2026 | Option exercise | +4,660 | $4.95 | $23.07K | 11,889 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 6, 2026 | Sale(10b5-1 plan) | −4,660 | $213.95 | $997.01K | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 5, 2026 | Option exercise | +45,004 | $4.95 | $222.77K | 52,233 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 5, 2026 | Sale(10b5-1 plan) | −45,004 | $212.01 | $9.54M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jul 1, 2026 | Sale(10b5-1 plan) | −49,666 | $240.25 | $11.93M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jul 1, 2026 | Option exercise | +49,666 | $4.95 | $245.85K | 56,895 |
| Roger Jeffs Director | Jun 11, 2026 | Sale(10b5-1 plan) | −286 | $249.12 | $71.25K | 58,367 |
| Roger Jeffs Director | Jun 10, 2026 | Sale(10b5-1 plan) | −286 | $246.18 | $70.41K | 58,653 |
| Mark Coleman Director | Jun 10, 2026 | Sale(10b5-1 plan) | −643 | $249.00 | $160.11K | 30,389 |
| Susan Mahony Director | Jun 10, 2026 | Sale(10b5-1 plan) | −300 | $246.18 | $73.85K | 829 |
| Susan Mahony Director | Jun 9, 2026 | Sale(10b5-1 plan) | −300 | $237.21 | $71.16K | 1,129 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jun 9, 2026 | Sale(10b5-1 plan) | −49,670 | $241.01 | $11.97M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jun 9, 2026 | Option exercise | +49,670 | $4.95 | $245.87K | 56,899 |
| Nick Pizzie Chief Financial Officer | Jun 9, 2026 | Sale(10b5-1 plan) | −33,000 | $240.09 | $7.92M | 42,867 |
| Nick Pizzie Chief Financial Officer | Jun 9, 2026 | Option exercise | +33,000 | $3.50 | $115.50K | 75,867 |
| Roger Jeffs Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 58,939 |
| Mark Coleman Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 31,032 |
| Susan Mahony Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 1,429 |
| Mark E. Saad Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 11,431 |
| Mark Coleman Director | Jun 2, 2026 | Sale(10b5-1 plan) | −5,537 | $223.39 | $1.24M | 29,603 |
| Mark Coleman Director | Jun 1, 2026 | Sale(10b5-1 plan) | −6,000 | $230.30 | $1.38M | 35,140 |
| Mark Coleman Director | May 29, 2026 | Sale(10b5-1 plan) | −6,000 | $233.46 | $1.40M | 41,140 |
| Mark L. Jacobson Chief Operating Officer | May 5, 2026 | Option exercise | +233 | $12.95 | $3.02K | 233 |
| Mark L. Jacobson Chief Operating Officer | May 5, 2026 | Sale(10b5-1 plan) | −233 | $228.18 | $53.17K | 0 |
| Mark L. Jacobson Chief Operating Officer | May 4, 2026 | Sale(10b5-1 plan) | −4,517 | $227.94 | $1.03M | 0 |
| Mark L. Jacobson Chief Operating Officer | May 4, 2026 | Option exercise | +4,517 | $12.95 | $58.50K | 4,517 |
| Ari Maizel Chief Commercial Officer | Apr 22, 2026 | Option exercise | +7,500 | $70.73 | $530.48K | 7,500 |
| Ari Maizel Chief Commercial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −7,500 | $182.42 | $1.37M | 0 |
| Mark Coleman Director | Feb 26, 2026 | Sale(10b5-1 plan) | −25,000 | $161.11 | $4.03M | 47,140 |
| Mark L. Jacobson Chief Operating Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −35,378 | $161.88 | $5.73M | 0 |
| Mark L. Jacobson Chief Operating Officer | Feb 26, 2026 | Option exercise | +35,378 | $2.85 | $100.83K | 35,378 |
| Mark Coleman Director | Feb 23, 2026 | Option exercise | +6,250 | $4.95 | $30.94K | 72,140 |
| Mark Coleman Director | Feb 20, 2026 | Option exercise | +12,485 | $4.95 | $61.80K | 65,890 |
| Mark Coleman Director | Feb 10, 2026 | Option exercise | +5,193 | $8.02 | $41.65K | 53,405 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Feb 2, 2026 | Option exercise | +32,410 | $8.02 | $259.93K | 39,639 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Feb 2, 2026 | Sale(10b5-1 plan) | −32,410 | $185.60 | $6.02M | 7,229 |
| Nick Pizzie Chief Financial Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −12,000 | $187.92 | $2.26M | 42,588 |
| Nick Pizzie Chief Financial Officer | Jan 22, 2026 | Option exercise | +12,000 | $3.50 | $42.00K | 54,588 |
| Ari Maizel Chief Commercial Officer | Jan 21, 2026 | Option exercise | +7,500 | $70.73 | $530.48K | 7,500 |
| Ari Maizel Chief Commercial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −7,500 | $184.44 | $1.38M | 0 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 7, 2026 | Option exercise | +31,261 | $8.02 | $250.71K | 38,490 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 7, 2026 | Sale(10b5-1 plan) | −31,261 | $170.38 | $5.33M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 6, 2026 | Option exercise | +29,450 | $8.02 | $236.19K | 36,679 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 6, 2026 | Sale(10b5-1 plan) | −29,450 | $172.33 | $5.08M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 5, 2026 | Sale(10b5-1 plan) | −78,703 | $171.28 | $13.48M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 5, 2026 | Option exercise | +78,703 | $8.02 | $631.20K | 85,932 |
| Mark E. Saad Director | Dec 31, 2025 | Option exercise | +31,346 | $4.95 | $155.16K | 41,348 |
| Mark E. Saad Director | Dec 31, 2025 | Sale(10b5-1 plan) | −31,346 | $165.18 | $5.18M | 10,002 |
| Mark E. Saad Director | Dec 31, 2025 | Sale(10b5-1 plan) | −6,231 | $165.18 | $1.03M | 10,002 |
| Mark E. Saad Director | Dec 31, 2025 | Option exercise | +6,231 | $8.02 | $49.97K | 16,233 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 4, 2025 | Sale(10b5-1 plan) | −10,558 | $148.18 | $1.56M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 4, 2025 | Option exercise | +10,558 | $8.02 | $84.68K | 17,787 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 3, 2025 | Option exercise | +20,163 | $8.02 | $161.71K | 27,392 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 3, 2025 | Sale(10b5-1 plan) | −20,163 | $146.94 | $2.96M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 2, 2025 | Option exercise | +49,252 | $8.02 | $395.00K | 56,481 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 2, 2025 | Sale(10b5-1 plan) | −49,252 | $144.59 | $7.12M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Nov 5, 2025 | Option exercise | +21,775 | $8.02 | $174.64K | 29,004 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Nov 5, 2025 | Sale(10b5-1 plan) | −21,775 | $134.49 | $2.93M | 7,229 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jacobson Mark Officer | Sep 3, 2026 | 10,000 | $2.08M | Sep 3, 2026 | Acquired as compensation -- Stock Options |
| Tabuteau Herriot Officer | Aug 6, 2026 | 4,660 | $979.21K | Aug 6, 2026 | Acquired as compensation -- Stock Options |
| Tabuteau Herriot Officer | Aug 5, 2026 | 45,004 | $9.58M | Aug 5, 2026 | Acquired as compensation -- Stock Options |
| Tabuteau Herriot Officer | Jul 1, 2026 | 49,666 | $11.95M | Jul 1, 2026 | Acquired as compensation -- Stock Options |
| Roger Jeffs Director | Jun 11, 2026 | 286 | $71.25K | Jun 11, 2026 | Restricted Stock Lapse |
| Mark Coleman Director | Jun 10, 2026 | 643 | $160.11K | Jun 10, 2026 | Restricted Stock Lapse |
| Roger Jeffs Director | Jun 10, 2026 | 286 | $70.41K | Jun 10, 2026 | Restricted Stock Lapse |
| Susan Mahony Director | Jun 10, 2026 | 300 | $73.85K | Jun 10, 2026 | Restricted Stock Lapse |
| Tabuteau Herriot Officer | Jun 9, 2026 | 49,670 | $12.20M | Jun 9, 2026 | Acquired as compensation -- Stock Options |
| Nick Pizzie Officer | Jun 9, 2026 | 33,000 | $7.92M | Jun 9, 2026 | Employee Stock Option Exercise |
| Susan Mahony Director | Jun 9, 2026 | 300 | $71.16K | Jun 9, 2026 | Restricted Stock Lapse |
| Mark Coleman Director | Jun 2, 2026 | 5,537 | $1.24M | Jun 2, 2026 | Exercise and Hold |
| Mark Coleman Director | Jun 1, 2026 | 6,000 | $1.38M | Jun 1, 2026 | Exercise and Hold |
| Mark Coleman Director | May 29, 2026 | 6,000 | $1.40M | May 29, 2026 | Exercise and Hold |
| Jacobson Mark Officer | May 5, 2026 | 233 | $51.97K | May 5, 2026 | Acquired as compensation -- Stock Options |